Select Your Region
Americas
Europe
Africa
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- Clinical Study Details
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Autoimmune Disorder Multiple Sclerosis (MS) Relapsing-Remitting Multiple Sclerosis (RRMS)
Study results
LPS WA21493 Final Results May 2025 English
(PDF, 0.3 MB)
LPS WA21493 Final Results May 2025 Belgium Dutch
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Belgium French
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Belgium German
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Bulgarian
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Canada French
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Czech
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 France French
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Germany German
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Italy Italian
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Mexico Spanish
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Romanian
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Russia Russian
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Serbian
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Serbian Cyrillic
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Slovak
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Spain Catalan
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Spain Galician
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Spain Spanish
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Switzerland French
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Switzerland German
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Switzerland Italian
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Ukraine Russian
(PDF, 0.4 MB)
LPS WA21493 Final Results May 2025 Ukraine Ukrainian
(PDF, 0.4 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com